ALS-4
Staphylococcus aureus infections (including MRSA)
Pre-clinicalActive
Key Facts
Indication
Staphylococcus aureus infections (including MRSA)
Phase
Pre-clinical
Status
Active
Company
About Aptorum Group
Aptorum Group is a publicly traded biopharmaceutical company dedicated to discovering and developing innovative therapies for diseases with significant unmet needs. Its strategy involves utilizing its proprietary platforms, including the ALS-4 platform for anti-infectives and the orphan drug-focused platform, to build a diversified pipeline. The company is advancing multiple candidates through early clinical stages while exploring strategic partnerships to accelerate development.
View full company profile